Human CellExp™ ErbB4/HER4, human recombinant

Catalog number
7401-50
Name
Human CellExp™ ErbB4/HER4, human recombinant
Size
50 μg
Price
697.00 EUR
Supplier

Details

Target
ErbB4
Background
Receptor tyrosine-protein kinase erbB-4 (ErbB4), also known as Her4, is a single-pass type I transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB4 is expressed in normal skeletal muscle, heart, pituitary, brain and several breast carcinomas. ERBB4 contains multiple furin-like cysteine rich domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins-2 and -3, heparin-binding EGF-like growth factor and betacellulin. Ligand binding induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. ErbB4 appears to play important roles in neuronal development, development of the heart and cancer. ERBB4 has been shown to interact with: DLG4, NRG1, STAT5A, and YAP1. Mutations in this gene have been associated with cancer. Other single-nucleotide polymorphisms and a risk haplotype have been linked to schizophrenia.
Concentration
N/A
Molecular weight
This protein is fused with 6×his tag at the C-terminus and has a calculated MW of 70.6 kDa expressed. The predicted N-terminal is Glu26. Protein migrates as 95-110 kDa in reduced SDS-PAGE due to glycosylation.
Synonym
HER4, ErbB4, MGC138404, p180erbB4
Other name
HER4, ErbB4, MGC138404, p180erbB4
NCBI gene number
2066
NCBI gene
ErbB4
Gene source
Human
NCBI number
Q15303
Recombinant
Yes
Source
HEK293 cells
Purification
≥95%
Tested applications
SDS-PAGE, N/A
Tested activity
N/A
Biological activity
Measured by its ability to inhibit the biological activity of Neuregulin-1-β1 on MCF-7 human breast cancer cells, in the presence of 10 ng/mL of Recombinant Human NRG1-β1/HRG1-β1 Extracellular Domain. The ED50 for this effect is typically 0.2-2.5 μg/mL.
Reesults
Measured by its ability to inhibit the biological activity of Neuregulin-1-β1 on MCF-7 human breast cancer cells, in the presence of 10 ng/mL of Recombinant Human NRG1-β1/HRG1-β1 Extracellular Domain. The ED50 for this effect is typically 0.2-2.5 μg/mL.
Binding ability
N/A
Unit
N/A
Storage condition
-20°C
Shipping under
Gel Pack
Physical appearance
Lyophilized
Physical properties
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.
How to reconstitute
Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.
Aa sequence
N/A
Before use
Centrifuge the vial prior to opening.
Notes
For Research Use Only! Not to be used in humans
Properties
Human proteins, cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies. Modern humans (Homo sapiens, primarily ssp. Homo sapiens sapiens). Depending on the epitopes used human ELISA kits can be cross reactive to many other species. Mainly analyzed are human serum, plasma, urine, saliva, human cell culture supernatants and biological samples.
Additional source
Recombinants or rec. proteins
Group
recombinants